Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243191 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
A Phase 2 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00243191 is a Phase 2 study that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 18 participants.
The verdict
NCT00243191, a Phase 2 study, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.
Interventions
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00243191
The ClinicalTrials.gov registry entry for NCT00243191 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which imatinib mesylate is the first listed.
NCT00243191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00243191 about?
NCT00243191 is a clinical study titled "Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans". The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.
What is the current status of trial NCT00243191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2006-05. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00243191?
The interventions under investigation include: imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00243191?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.